BIOGEN INC (IDP.DE) Fundamental Analysis & Valuation
FRA:IDP • US09062X1037
Current stock price
157.02 EUR
-3.76 (-2.34%)
Last:
This IDP.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. IDP.DE Profitability Analysis
1.1 Basic Checks
- IDP had positive earnings in the past year.
- IDP had a positive operating cash flow in the past year.
- IDP had positive earnings in each of the past 5 years.
- IDP had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
- With a decent Return On Assets value of 4.39%, IDP is doing good in the industry, outperforming 77.78% of the companies in the same industry.
- With a decent Return On Equity value of 7.08%, IDP is doing good in the industry, outperforming 79.01% of the companies in the same industry.
- IDP has a Return On Invested Capital of 8.93%. This is amongst the best in the industry. IDP outperforms 82.72% of its industry peers.
- The Average Return On Invested Capital over the past 3 years for IDP is below the industry average of 12.00%.
- The last Return On Invested Capital (8.93%) for IDP is above the 3 year average (8.93%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.39% | ||
| ROE | 7.08% | ||
| ROIC | 8.93% |
ROA(3y)4.85%
ROA(5y)6.69%
ROE(3y)8.23%
ROE(5y)12.34%
ROIC(3y)8.93%
ROIC(5y)10.93%
1.3 Margins
- IDP's Profit Margin of 13.07% is fine compared to the rest of the industry. IDP outperforms 79.01% of its industry peers.
- IDP's Profit Margin has declined in the last couple of years.
- IDP has a better Operating Margin (27.94%) than 85.19% of its industry peers.
- IDP's Operating Margin has declined in the last couple of years.
- IDP has a better Gross Margin (75.69%) than 66.67% of its industry peers.
- IDP's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 27.94% | ||
| PM (TTM) | 13.07% | ||
| GM | 75.69% |
OM growth 3Y-3.78%
OM growth 5Y-5.27%
PM growth 3Y-24.15%
PM growth 5Y-15.17%
GM growth 3Y-0.7%
GM growth 5Y-2.57%
2. IDP.DE Health Analysis
2.1 Basic Checks
- IDP has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
- The number of shares outstanding for IDP has been increased compared to 1 year ago.
- The number of shares outstanding for IDP has been reduced compared to 5 years ago.
- The debt/assets ratio for IDP has been reduced compared to a year ago.
2.2 Solvency
- An Altman-Z score of 3.33 indicates that IDP is not in any danger for bankruptcy at the moment.
- With a Altman-Z score value of 3.33, IDP perfoms like the industry average, outperforming 59.26% of the companies in the same industry.
- IDP has a debt to FCF ratio of 3.11. This is a good value and a sign of high solvency as IDP would need 3.11 years to pay back of all of its debts.
- The Debt to FCF ratio of IDP (3.11) is better than 85.19% of its industry peers.
- IDP has a Debt/Equity ratio of 0.34. This is a healthy value indicating a solid balance between debt and equity.
- IDP has a Debt to Equity ratio (0.34) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.34 | ||
| Debt/FCF | 3.11 | ||
| Altman-Z | 3.33 |
ROIC/WACC0.97
WACC9.21%
2.3 Liquidity
- IDP has a Current Ratio of 2.68. This indicates that IDP is financially healthy and has no problem in meeting its short term obligations.
- IDP has a Current ratio (2.68) which is comparable to the rest of the industry.
- IDP has a Quick Ratio of 2.03. This indicates that IDP is financially healthy and has no problem in meeting its short term obligations.
- IDP has a Quick ratio (2.03) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.68 | ||
| Quick Ratio | 2.03 |
3. IDP.DE Growth Analysis
3.1 Past
- IDP shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -7.16%.
- The earnings per share for IDP have been decreasing by -14.17% on average. This is quite bad
- IDP shows a small growth in Revenue. In the last year, the Revenue has grown by 2.22%.
- The Revenue has been decreasing by -5.96% on average over the past years.
EPS 1Y (TTM)-7.16%
EPS 3Y-6.07%
EPS 5Y-14.17%
EPS Q2Q%-42.15%
Revenue 1Y (TTM)2.22%
Revenue growth 3Y-0.93%
Revenue growth 5Y-5.96%
Sales Q2Q%-7.14%
3.2 Future
- Based on estimates for the next years, IDP will show a small growth in Earnings Per Share. The EPS will grow by 3.53% on average per year.
- The Revenue is expected to decrease by -0.48% on average over the next years.
EPS Next Y5.45%
EPS Next 2Y3.4%
EPS Next 3Y3.98%
EPS Next 5Y3.53%
Revenue Next Year-3.54%
Revenue Next 2Y-1.96%
Revenue Next 3Y-0.91%
Revenue Next 5Y-0.48%
3.3 Evolution
- The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. IDP.DE Valuation Analysis
4.1 Price/Earnings Ratio
- Based on the Price/Earnings ratio of 12.00, the valuation of IDP can be described as correct.
- Compared to the rest of the industry, the Price/Earnings ratio of IDP indicates a rather cheap valuation: IDP is cheaper than 92.59% of the companies listed in the same industry.
- Compared to an average S&P500 Price/Earnings ratio of 27.42, IDP is valued rather cheaply.
- The Price/Forward Earnings ratio is 11.39, which indicates a very decent valuation of IDP.
- Based on the Price/Forward Earnings ratio, IDP is valued cheaper than 97.53% of the companies in the same industry.
- The average S&P500 Price/Forward Earnings ratio is at 22.24. IDP is valued slightly cheaper when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 12 | ||
| Fwd PE | 11.39 |
4.2 Price Multiples
- Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of IDP indicates a rather cheap valuation: IDP is cheaper than 90.12% of the companies listed in the same industry.
- Based on the Price/Free Cash Flow ratio, IDP is valued cheaply inside the industry as 97.53% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 13.35 | ||
| EV/EBITDA | 8.26 |
4.3 Compensation for Growth
- The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
- IDP has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)2.2
PEG (5Y)N/A
EPS Next 2Y3.4%
EPS Next 3Y3.98%
5. IDP.DE Dividend Analysis
5.1 Amount
- IDP does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
IDP.DE Fundamentals: All Metrics, Ratios and Statistics
FRA:IDP (4/24/2026, 7:00:00 PM)
157.02
-3.76 (-2.34%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-06 2026-02-06/bmo
Earnings (Next)04-29 2026-04-29/bmo
Inst Owners98.03%
Inst Owner ChangeN/A
Ins Owners0.12%
Ins Owner ChangeN/A
Market Cap23.04B
Revenue(TTM)9.89B
Net Income(TTM)1.29B
Analysts73.02
Price Target183.33 (16.76%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)21.18%
Min EPS beat(2)20.87%
Max EPS beat(2)21.48%
EPS beat(4)4
Avg EPS beat(4)24.64%
Min EPS beat(4)17.28%
Max EPS beat(4)38.92%
EPS beat(8)8
Avg EPS beat(8)17.2%
EPS beat(12)12
Avg EPS beat(12)12.76%
EPS beat(16)15
Avg EPS beat(16)12.81%
Revenue beat(2)2
Avg Revenue beat(2)3.75%
Min Revenue beat(2)1.26%
Max Revenue beat(2)6.23%
Revenue beat(4)4
Avg Revenue beat(4)6.45%
Min Revenue beat(4)1.26%
Max Revenue beat(4)11.62%
Revenue beat(8)6
Avg Revenue beat(8)2.98%
Revenue beat(12)9
Avg Revenue beat(12)2.26%
Revenue beat(16)11
Avg Revenue beat(16)1.92%
PT rev (1m)3.56%
PT rev (3m)12.35%
EPS NQ rev (1m)-2.21%
EPS NQ rev (3m)-15.11%
EPS NY rev (1m)0.27%
EPS NY rev (3m)4.3%
Revenue NQ rev (1m)0.61%
Revenue NQ rev (3m)-0.78%
Revenue NY rev (1m)0.42%
Revenue NY rev (3m)1.67%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 12 | ||
| Fwd PE | 11.39 | ||
| P/S | 2.72 | ||
| P/FCF | 13.35 | ||
| P/OCF | 12.22 | ||
| P/B | 1.48 | ||
| P/tB | 10.42 | ||
| EV/EBITDA | 8.26 |
EPS(TTM)13.08
EY8.33%
EPS(NY)13.79
Fwd EY8.78%
FCF(TTM)11.77
FCFY7.49%
OCF(TTM)12.85
OCFY8.18%
SpS57.63
BVpS106.38
TBVpS15.08
PEG (NY)2.2
PEG (5Y)N/A
Graham Number176.938 (12.69%)
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.39% | ||
| ROE | 7.08% | ||
| ROCE | 10.59% | ||
| ROIC | 8.93% | ||
| ROICexc | 10.46% | ||
| ROICexgc | 35.29% | ||
| OM | 27.94% | ||
| PM (TTM) | 13.07% | ||
| GM | 75.69% | ||
| FCFM | 20.42% |
ROA(3y)4.85%
ROA(5y)6.69%
ROE(3y)8.23%
ROE(5y)12.34%
ROIC(3y)8.93%
ROIC(5y)10.93%
ROICexc(3y)9.96%
ROICexc(5y)13.03%
ROICexgc(3y)38.5%
ROICexgc(5y)36.85%
ROCE(3y)10.59%
ROCE(5y)12.95%
ROICexgc growth 3Y4.85%
ROICexgc growth 5Y-4.35%
ROICexc growth 3Y-13.95%
ROICexc growth 5Y-14.37%
OM growth 3Y-3.78%
OM growth 5Y-5.27%
PM growth 3Y-24.15%
PM growth 5Y-15.17%
GM growth 3Y-0.7%
GM growth 5Y-2.57%
F-Score4
Asset Turnover0.34
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.34 | ||
| Debt/FCF | 3.11 | ||
| Debt/EBITDA | 1.77 | ||
| Cap/Depr | 23.77% | ||
| Cap/Sales | 1.87% | ||
| Interest Coverage | 10.46 | ||
| Cash Conversion | 62.22% | ||
| Profit Quality | 156.18% | ||
| Current Ratio | 2.68 | ||
| Quick Ratio | 2.03 | ||
| Altman-Z | 3.33 |
F-Score4
WACC9.21%
ROIC/WACC0.97
Cap/Depr(3y)46.72%
Cap/Depr(5y)49.51%
Cap/Sales(3y)2.92%
Cap/Sales(5y)2.77%
Profit Quality(3y)138.91%
Profit Quality(5y)133.83%
High Growth Momentum
Growth
EPS 1Y (TTM)-7.16%
EPS 3Y-6.07%
EPS 5Y-14.17%
EPS Q2Q%-42.15%
EPS Next Y5.45%
EPS Next 2Y3.4%
EPS Next 3Y3.98%
EPS Next 5Y3.53%
Revenue 1Y (TTM)2.22%
Revenue growth 3Y-0.93%
Revenue growth 5Y-5.96%
Sales Q2Q%-7.14%
Revenue Next Year-3.54%
Revenue Next 2Y-1.96%
Revenue Next 3Y-0.91%
Revenue Next 5Y-0.48%
EBIT growth 1Y8.4%
EBIT growth 3Y-4.68%
EBIT growth 5Y-10.91%
EBIT Next Year17.07%
EBIT Next 3Y5.07%
EBIT Next 5Y1.28%
FCF growth 1Y-19.74%
FCF growth 3Y20.95%
FCF growth 5Y-11.3%
OCF growth 1Y-23.33%
OCF growth 3Y16.78%
OCF growth 5Y-12.22%
BIOGEN INC / IDP.DE Fundamental Analysis FAQ
What is the ChartMill fundamental rating of BIOGEN INC (IDP.DE) stock?
ChartMill assigns a fundamental rating of 5 / 10 to IDP.DE.
What is the valuation status for IDP stock?
ChartMill assigns a valuation rating of 7 / 10 to BIOGEN INC (IDP.DE). This can be considered as Undervalued.
How profitable is BIOGEN INC (IDP.DE) stock?
BIOGEN INC (IDP.DE) has a profitability rating of 6 / 10.
Can you provide the PE and PB ratios for IDP stock?
The Price/Earnings (PE) ratio for BIOGEN INC (IDP.DE) is 12 and the Price/Book (PB) ratio is 1.48.
What is the earnings growth outlook for BIOGEN INC?
The Earnings per Share (EPS) of BIOGEN INC (IDP.DE) is expected to grow by 5.45% in the next year.